Glucocorticoid

Emapalumab's efficacy confirmed by sensitivity analysis presented at ESID2020

Saturday, October 17, 2020 - 1:33pm

"We remain committed to making emapalumab accessible to patients affected by this severe condition around the world."

Key Points: 
  • "We remain committed to making emapalumab accessible to patients affected by this severe condition around the world."
  • A high unmet medical need exists among these patients despite today's standard-of-care therapy, glucocorticoids and etoposide, with or without cyclosporine.
  • The pivotal study used clinically objective response criteria to define the primary endpoint of overall response rate to emapalumab in primary HLH.
  • The sensitivity analysis supports the use of the clinically objective ORR as a primary endpoint in studies of primary HLH.

Neurocrine Biosciences Reports Positive Phase II Data for Crinecerfont in Adults with Congenital Adrenal Hyperplasia at ENDO Online 2020

Monday, June 8, 2020 - 4:01pm

These data suggest that crinecerfont has the potential to improve CAH symptoms and to reduce the burden of daily glucocorticoid exposure for these patients.

Key Points: 
  • These data suggest that crinecerfont has the potential to improve CAH symptoms and to reduce the burden of daily glucocorticoid exposure for these patients.
  • Neurocrine Biosciences plans to initiate a single, global registrational study of crinecerfont in adult patients with classic CAH in the second half of 2020.
  • Classic CAH is a genetic disorder, in which an enzyme deficiency alters the production of adrenal steroids.
  • The Phase II open-label, multiple-dose, dose-finding study assessed the safety, tolerability, pharmacokinetics and pharmacodynamics of crinecerfont in 18 adults with classic 21-hydroxylase deficiency CAH.

ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist and CD73 Inhibitor Programs at AACR-NCI-EORTC Annual Conference

Monday, October 28, 2019 - 12:37pm

The ORIC-101 preclinical data were presented in abstract LB-A10, "ORIC-101 Overcomes Glucocorticoid-Driven Resistance to Enzalutamide in Castration-Resistant Prostate Cancer."

Key Points: 
  • The ORIC-101 preclinical data were presented in abstract LB-A10, "ORIC-101 Overcomes Glucocorticoid-Driven Resistance to Enzalutamide in Castration-Resistant Prostate Cancer."
  • The data demonstrated that glucocorticoids promote tumor cell growth, stimulate expression of androgen regulated genes, and drive resistance to enzalutamide.
  • Preclinical data from ORIC's second program were presented in abstract LB-A19, "Intratumoral Immunosuppression is Reversed by Blocking Adenosine Production with an Oral Inhibitor of CD73."
  • ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance.

Congenital Adrenal Hyperplasia Epiomic Epidemiology Forecasts 2018-2028

Monday, September 17, 2018 - 10:15pm

The "Congenital Adrenal Hyperplasia Forecast In 31 Major Markets 2018-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Congenital Adrenal Hyperplasia Forecast In 31 Major Markets 2018-2028" report has been added to ResearchAndMarkets.com's offering.
  • Congenital adrenal hyperplasia (CAH) is a group of genetic disorders associated with deficiencies of several adrenal enzymes which lead to abnormal production of glucocorticoids, mineralocorticoids and sex steroids.
  • This, in turn, affects metabolism, sodium and water balance and the development of primary or secondary sex characteristics.
  • CAH can occur in classic (severe) or non-classic (mild) forms depending on the amount of residue enzyme activity.